Abstract
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the programmed cell death 1 (PD-1) or its ligand, PD-1 ligand 1 (PD-L1), including information on their clinical indications and associated companion diagnostics. The information is further discussed with strategies for identifying predictive biomarkers to guide the clinical use of PD-1/PD-L1-targeted therapies.
Keywords:
biomarker; cancer immunotherapy; companion diagnostic; immune checkpoint inhibitor.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
B7-H1 Antigen / antagonists & inhibitors
-
Biomarkers, Tumor / analysis*
-
Clinical Decision-Making / methods
-
Diagnostic Test Approval / legislation & jurisprudence
-
Drug Approval / legislation & jurisprudence
-
Drug Approval / statistics & numerical data
-
Humans
-
Immune Checkpoint Inhibitors / pharmacology
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Neoplasms / diagnosis
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Reagent Kits, Diagnostic*
-
United States
-
United States Food and Drug Administration / legislation & jurisprudence*
-
United States Food and Drug Administration / statistics & numerical data
Substances
-
B7-H1 Antigen
-
Biomarkers, Tumor
-
CD274 protein, human
-
Immune Checkpoint Inhibitors
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Reagent Kits, Diagnostic